Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

The Cochrane Database of Systematic Reviews
Angela C WebsterJonathan C Craig

Abstract

Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action but an uncertain clinical role. To investigate the benefits and harms of immunosuppressive regimens containing TOR-I when compared to other regimens as initial therapy for kidney transplant recipients. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (in The Cochrane Library, issue 2, 2005), MEDLINE (1966-June 2005), EMBASE (1980-June 2005), the specialised register of the Cochrane Renal Group (June 2005)., and contacted authors and pharmaceutical companies to identify relevant studies. All randomised controlled trials (RCTs) and quasi-RCTs where drug regimens containing TOR-I were compared to alternative drug regimens in the immediate post-transplant period were included, without age restriction, dosage or language of report. Two reviewers independently assessed trials for eligibility and quality, and extracted data. Results are expressed as relative risk (RR) or weight mean difference (MD) with 95% confidence intervals (CI). Thirty three trials (142 reports) were included (sirolimus (27), everolimus (5), head-to-head (1)). When TOR-I replaced CNI there was no difference in acute rejec...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jun 27, 1995·Transplantation·B J NankivellJ R Chapman
Nov 12, 1994·BMJ : British Medical Journal·K DickersinC Lefebvre
Apr 1, 1997·Clinical and Experimental Immunology·S M StepkowskiB D Kahan
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Mar 4, 2000·The New England Journal of Medicine·S HariharanD Stablein
Mar 9, 2000·Transplantation·O ViklickýU Heemann
Jan 3, 2001·Kidney International·R N SaundersM L Nicholson
May 30, 2001·Transplantation Proceedings·C PonticelliT Mathew
Jul 14, 2001·Clinical Pharmacology and Therapeutics·B D Kahan, W G Kramer
Oct 5, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J A VelosaM D Stegall
Oct 17, 2001·Transplantation·B D Kahan, J S Camardo
Jan 24, 2002·Therapeutic Drug Monitoring·Björn Nashan
Feb 5, 2002·Expert Opinion on Pharmacotherapy·B D Kahan
Feb 22, 2002·The New England Journal of Medicine·Manuel PascualA Benedict Cosimi
Jul 18, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Conrad B Blum
Jul 19, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·José M MoralesUNKNOWN Sirolimus European Renal Transplant Study Group
Dec 3, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Stephen P McDonaldUNKNOWN Australia and New Zealand Dialysis and Transplant Registry
Dec 20, 2002·Transplantation·Thomas A GonwaUNKNOWN Sirolimus Renal Function Study Group
Mar 13, 2003·Kidney International·Mary B LeonardDenis F Geary
Apr 30, 2003·Transplantation·Steven ParaskevasArthur J Matas
May 14, 2003·Transplantation Proceedings·B CharpentierUNKNOWN Sirolimus European Renal Transplant Study
May 14, 2003·Transplantation Proceedings·G R RussUNKNOWN Australian Rapamune-Tacrolimus Study Group
May 14, 2003·Transplantation Proceedings·M D StegallJ Velosa
May 14, 2003·Transplantation Proceedings·C LegendreUNKNOWN Sirolimus European Renal Transplant Study Group
May 20, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·John M KovarikChristiane Rordorf
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman

❮ Previous
Next ❯

Citations

May 1, 2010·Journal of the American Society of Nephrology : JASN·Martin P GallagherAngela C Webster
Sep 1, 2016·Health Technology Assessment : HTA·Tracey Jones-HughesRob Anderson
Dec 4, 2015·The Cochrane Database of Systematic Reviews·Martin WagnerKatrin Uhlig
Aug 2, 2016·Nature Reviews. Nephrology·Daniel FantusAngus W Thomson
Sep 25, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·N J Mueller
Oct 11, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Natasha A DetersJenny E Gunton
Dec 17, 2019·The Cochrane Database of Systematic Reviews·Deirdre HahnAngela C Webster
Jan 16, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G WaldemarUNKNOWN EFNS
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Oct 23, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
May 21, 2014·British Journal of Haematology·Toby A EyreKate Cwynarski
Jul 26, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·P Kent LangstonJason M Grayson
Jul 8, 2020·Journal of Clinical Medicine·Anna PerriAntonio Aversa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.